June 16, 2014 at 14:22 PM EDT
Markets rise as home builder sentiment advances

The markets traded modestly higher during the midday with the Dow rising 9 points to 16,785 as home builder sentiment rose for the first time this year. Nasdaq added 8 points to 4,318.

On the upside

The Food and Drug Administration granted Orphan Drug Designation to DARA BioSciences' (Nasdaq: DARA) experimental multiple myeloma treatment KRN5500.

Maxim lifted its price target on Achillion Pharmaceuticals (Nasdaq: ACHN) from $6 to $22.

Bluebird Bio (Nasdaq: BLUE) reported positive preliminary results for its gene therapy treatment LentiGlobin.

On the downside

Shares of Enteromedics (Nasdaq: ETRM) fell ahead of a Food and Drug Administration advisory panel review of the company's implantable weight loss device tomorrow.

Bernstein analyst Geoff Porges expects Vertex Pharmaceuticals' (Nasdaq: VRTX) cystic fibrosis combination treatments Kalydeco and VX-809 will fail.

Slowing revenue growth at Alibaba weighed downs shares of Yahoo (Nasdaq: YHOO), which holds a 22.6% stake in the Chinese e-commerce company.

In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 4 on the NYSE and by 10 to 9 on Nasdaq. The broader S&P 500 added 2 points to 1938. Bitcoin rose $17.33 or 2.94% to $589.58.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here